tazarotene has been researched along with Acne in 74 studies
tazarotene: a topical acetylenic retinoid; a topical kerytolytic
tazarotene : The ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In two phase 3 double-blind studies, participants 9 years of age and older with moderate-to-severe acne were randomized (1:1) to once-daily tazarotene 0." | 9.51 | Tazarotene 0.045% Lotion for Females With Acne: Analysis of Two Adult Age Groups. ( Baldwin, H; Callender, V; Cook-Bolden, F; Del Rosso, J; Guenin, E; Kircik, L; Stein Gold, L; Tanghetti, E; Zeichner, J, 2022) |
| "In two phase 3, double-blind, 12-week studies (NCT03168334; NCT03168321), participants aged ≥9 years with moderate-to-severe acne were randomized (1:1) to tazarotene 0." | 9.51 | Efficacy and Safety of Tazarotene 0.045% Lotion in Caucasian Adults With Moderate-to-Severe Acne. ( Callender, V; Cook-Bolden, F; Del Rosso, J; Draelos, Z; Guenin, E; Stein Gold, L; Tyring, S; Werschler, W; Zeichner, J, 2022) |
| "Patients aged ≥ 9 years with moderate-to-severe acne (score 3 or 4 on the Evaluator's Global Severity Score [EGSS]) were equally randomized to once-daily tazarotene 0." | 9.41 | Tazarotene 0.045% Lotion for Moderate-to-Severe Acne Patients: Pooled Phase 3 Analysis by Age and Sex. ( Del Rosso, JQ; Green, LJ; Guenin, E; Tanghetti, EA, 2021) |
| "BACKGROUND: Tazarotene has been extensively studied in clinical trials and is widely used to treat acne vulgaris (acne), with data suggesting that is one of the most potent topical retinoids." | 9.34 | Tazarotene 0.045% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Results from Two Phase 3 Trials ( Guenin, E; Lain, T; Martin, G; Pillai, R; Tanghetti, EA; Werschler, WP, 2020) |
| "In two phase 3, double-blind, vehicle-controlled 12-week studies, patients with moderate-to-severe acne (N=1,614) were randomized (1:1) to receive tazarotene 0." | 9.34 | New Polymeric Once-Daily Tazarotene 0.045% Lotion Formulation for Moderate-to-Severe Acne: Pooled Phase 3 Pediatric Analysis. ( Eichenfield, LF; Guenin, E; Martin, G; Pillai, R; Tanghetti, EA, 2020) |
| "In two phase 3 trials (NCT03168334, NCT03168321), participants with moderate-to-severe acne had significant symptom improvements after 12 weeks of treatment with tazarotene 0." | 9.34 | Effects of Tazarotene 0.045% Lotion on Quality of Life in Patients With Moderate-to-Severe Acne. ( Baldwin, H; Gold, M; Guenin, E; Katz, B; Kircik, LH; Lain, E; Loncaric, A; Pillai, R, 2020) |
| "Background: Tazarotene has been extensively studied in clinical trials and is widely used to treat acne vulgaris (acne)." | 9.30 | A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne Vulgaris ( Green, LJ; Guenin, E; Harris, S; Kircik, LH; Martin, G; Pillai, R; Tanghetti, EA, 2019) |
| "The present study was conducted to compare the efficacy and safety of tazarotene plus clindamycin against adapalene plus clindamycin in facial acne vulgaris." | 9.24 | Efficacy and Safety of Tazarotene 0.1% Plus Clindamycin 1% Gel Versus Adapalene 0.1% Plus Clindamycin 1% Gel in Facial Acne Vulgaris: A Randomized, Controlled Clinical Trial. ( Ashique Rahman, MA; Hota, D; Maiti, R; Parida, S; Sirka, CS; Srinivasan, A, 2017) |
| "Tazarotene, a retinoid pro-drug, is available in gel, cream and foam for the topical treatment of acne vulgaris." | 9.17 | Tazarotene foam versus tazarotene gel: a randomized relative bioavailability study in acne vulgaris. ( Alió Saenz, AB; Jarratt, M; Werner, CP, 2013) |
| "To evaluate the efficacy of 3 maintenance regimens (topical tazarotene, oral minocycline hydrochloride, or both) in sustaining improvement in acne." | 9.12 | Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. ( Leyden, J; Shalita, AR; Shupack, J; Strober, BE; Thiboutot, DM; Washenik, K; Webster, G, 2006) |
| "Topical retinoids offer highly effective treatment for both inflammatory and non-inflammatory acne, with tazarotene demonstrating greater efficacy than other topical retinoids." | 9.12 | Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double-blind, randomized parallel-group trial. ( Abramovits, W; Loven, K; Shalita, A; Solomon, B; Tanghetti, E, 2006) |
| "Results of clinical trials have shown that tazarotene cream used as monotherapy effectively reduces the number of both inflammatory and noninflammatory lesions in patients with acne vulgaris." | 9.11 | Topical tazarotene: The BEST (balancing efficacy, speed, and tolerability) in acne trial. ( Shalita, A, 2004) |
| "1% tazarotene gel therapy is a safe and effective new method of acne treatment." | 9.10 | Successful treatment of acne vulgaris using a new method: results of a randomized vehicle-controlled trial of short-contact therapy with 0.1% tazarotene gel. ( Bershad, S; Kranjac Singer, G; Lebwohl, M; Parente, JE; Persaud, AN; Sherer, DW; Tan, MH, 2002) |
| "A multicenter, investigator-masked, randomized, parallel-group study was performed in 440 patients with mild-to-moderate facial acne vulgaris to compare the efficacy and tolerability of tazarotene monotherapy with 3 combination regimens--tazarotene plus benzoyl peroxide gel, tazarotene plus erythromycin/benzoyl peroxide gel, and tazarotene plus clindamycin phosphate lotion." | 9.10 | Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. ( Draelos, ZD; Tanghetti, EA, 2002) |
| "Tazarotene and adapalene are recently introduced topical retinoids that are useful in the treatment of acne vulgaris." | 9.09 | Comparison of treatment of acne vulgaris with alternate-day applications of tazarotene 0.1% gel and once-daily applications of adapalene 0.1% gel: a randomized trial. ( Draelos, Z; Kakita, L; Leyden, J; Lowe, N, 2001) |
| "Topical tazarotene has shown superior efficacy over other topical retinoids, including adapalene and tretinoin, in the treatment of mild to moderate acne." | 8.82 | Meta-analysis of topical tazarotene in the treatment of mild to moderate acne. ( Leyden, JJ, 2004) |
| "Adapalene (Differin) is a retinoid agent indicated for the topical treatment of acne vulgaris." | 8.82 | Spotlight on adapalene in acne vulgaris. ( Noble, S; Scott, LJ; Waugh, J, 2004) |
| "1% gel in the treatment of acne vulgaris have been compared with those of tretinoin 0." | 8.80 | Tazarotene versus tretinoin or adapalene in the treatment of acne vulgaris. ( Kakita, L, 2000) |
| "Tazarotene (AGN 190168) is a new acetylenic retinoid which is effective for the topical treatment of patients with stable plaque psoriasis and mild to moderate acne vulgaris." | 8.80 | Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. ( Matsumoto, RM; Tang-Liu, DD; Usansky, JI, 1999) |
| "Background: As current tazarotene formulations indicated for acne (0." | 7.96 | Novel Polymeric Lotion Formulation of Once-Daily Tazarotene (0.045%) for Moderate-to-Severe Acne: Pooled Phase 3 Analysis. ( Guenin, E; Harris, S; Lain, E; Loncaric, A; Pillai, R; Tanghetti, EA; Werschler, WP, 2020) |
| "The objective of this study was to develop and evaluate a novel microemulsion based gel formulation containing tazarotene for targeted topical therapy of acne." | 7.83 | Novel microemulsion-based gel formulation of tazarotene for therapy of acne. ( Parikh, JR; Patel, BG; Patel, MR; Patel, RB, 2016) |
| "Tazarotene is a synthetic retinoid that, depending on the concentration and vehicle, is approved by the US Food and Drug Administration for the topical treatment of acne vulgaris (AV) and plaque psoriasis." | 7.79 | A status report on topical tazarotene in the management of acne vulgaris. ( Del Rosso, JQ; Tanghetti, E, 2013) |
| "In these 2 studies in adolescent and adult patients with facial acne vulgaris, tazarotene 0." | 7.72 | Effects of tazarotene 0.1 % cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials. ( Berson, DS; Gibson, JR; Leyden, JJ; Parizadeh, D; Sefton, J; Shalita, AR; Thiboutot, DM; Walker, PS, 2004) |
| "Topical tazarotene is effective and well tolerated in the treatment of acne vulgaris and has been used successfully in diverse patient populations." | 7.72 | Topical tazarotene in acne vulgaris: treatment approaches. ( Anderson, DN; Callender, VD; Del Rosso, JQ; Tanghetti, EA; Zane, LT, 2004) |
| "Acne is likely less common in adult men because of the declining rate of sebum secretion observed with increasing age, and yet it can be more severe than in adult women." | 6.94 | Tazarotene 0.045% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Adult Males ( Cook-Bolden, FE; Gold, MH; Guenin, E, 2020) |
| "By contrast, median qualitative acne scar scores were the same for both treatment groups at baseline and did not significantly change following either treatment." | 6.90 | Topical Tazarotene Gel, 0.1%, as a Novel Treatment Approach for Atrophic Postacne Scars: A Randomized Active-Controlled Clinical Trial. ( Afra, TP; Dogra, S; Kumar, A; Narang, T; Razmi T, M, 2019) |
| "Acne is a multifactorial chronic dermatosis that can be effectively treated with adjuvant medications." | 6.78 | Clindamycin phosphate 1.2%-benzoyl peroxide (5% or 2.5%) plus tazarotene cream 0.1% for the treatment of acne. ( Dhawan, SS; Gwazdauskas, J, 2013) |
| "Tazarotene foam, 0." | 6.78 | The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies. ( Alió Saenz, AB; Feldman, SR; Werner, CP, 2013) |
| "To assess the safety and efficacy of dapsone gel 5%, an anti-inflammatory agent, in combination with tazarotene cream 0." | 6.76 | Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris. ( Dhawan, S; Downie, J; Draelos, Z; Germain, MA; Green, L; Kasteler, JS; Kircik, L; Ling, M; Oefelein, MG; Tanghetti, E, 2011) |
| "Tazarotene was approved by U." | 6.75 | Topical tazarotene cream (0.1%) in the treatment of facial acne: an open clinical trial. ( Choudhury, AM; Islam, MT; Paul, HK; Rahman, MA; Zakaria, AS, 2010) |
| "In the treatment of facial acne vulgaris, tazarotene plus clindamycin offers significantly greater efficacy than tretinoin plus clindamycin and has comparable tolerability." | 6.73 | Tazarotene 0.1 percent cream plus clindamycin 1 percent gel versus tretinoin 0.025 percent gel plus clindamycin 1 percent gel in the treatment of facial acne vulgaris. ( Dhawan, S; Kircik, L; Tanghetti, E; Torok, H, 2007) |
| "The adapalene arm was also therapeutically similar to the tazarotene arm in terms of the percent reduction in inflammatory and noninflammatory lesion counts at week 12, as well as in the assessments of acne severity and improvement." | 6.73 | Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris. ( Arsonnaud, S; Soto, P; Thiboutot, D, 2008) |
| "Adapalene gel was associated with fewer treatment-related adverse events than tazarotene cream (36% versus 58%, respectively), and less than half as many adverse events that were "definitely" related to study treatment than tazarotene cream (20% versus 45%, respectively)." | 6.73 | Adapalene 0.1% gel compared to tazarotene 0.1% cream in the treatment of acne vulgaris. ( Colón, LE; Gottschalk, RW; Johnson, LA; Pariser, D, 2008) |
| "Two separate, randomised, single-centre, nonblinded, parallel-group pharmacokinetic studies were conducted." | 6.71 | Pharmacokinetics of tazarotene cream 0.1% after a single dose and after repeat topical applications at clinical or exaggerated application rates in patients with acne vulgaris or photodamaged skin. ( Lew-Kaya, D; Sefton, J; Tang-Liu, DD; Walker, P; Yu, D; Yu, Z, 2003) |
| "Tazarotene 0." | 6.70 | Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. ( Berson, D; Fivenson, DP; Ling, M; Stein, LF; Tanghetti, EA; Webster, GF, 2001) |
| "Tazarotene treatment was associated with a significantly greater incidence of treatment success (defined as > or = 50% global improvement [67% vs 49%; P=." | 6.70 | Once-daily tazarotene 0.1 % gel versus once-daily tretinoin 0.1 % microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial. ( Berson, D; Lee, J; Leyden, JJ; Miller, B; Tanghetti, EA; Ung, M, 2002) |
| "Tazarotene gel was an effective, safe, and generally well-tolerated therapy for the treatment of acne vulgaris." | 6.69 | Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study. ( Chalker, DK; Chandraratna, RA; Gibson, JR; Griffith, RF; Herbert, AA; Hickman, JG; Lew-Kaya, DA; Lue, JC; Maloney, JM; Miller, BH; Sefton, J; Shalita, AR; Tschen, EH, 1999) |
| "Tazarotene is a pro-drug of tazarotenic acid, a receptor-selective retinoid, which has shown efficacy in the treatment of these disorders." | 6.41 | Topical tazarotene therapy for psoriasis, acne vulgaris, and photoaging. ( Guenther, LC, 2002) |
| "Tazarotene 0." | 5.72 | Tazarotene Lotion 0.045% for the Treatment of Acne ( Zip, C, 2022) |
| "Although truncal acne is thought to have the same pathophysiology as facial acne, treatment response may differ based on body area involvement." | 5.72 | Efficacy and Safety of Tazarotene Lotion, 0.045% in the Treatment of Truncal Acne Vulgaris. ( Kircik, L, 2022) |
| "In two phase 3, double-blind, 12-week studies (NCT03168334; NCT03168321), participants aged ≥9 years with moderate-to-severe acne were randomized (1:1) to tazarotene 0." | 5.51 | Efficacy and Safety of Tazarotene 0.045% Lotion in Caucasian Adults With Moderate-to-Severe Acne. ( Callender, V; Cook-Bolden, F; Del Rosso, J; Draelos, Z; Guenin, E; Stein Gold, L; Tyring, S; Werschler, W; Zeichner, J, 2022) |
| "In two phase 3 double-blind studies, participants 9 years of age and older with moderate-to-severe acne were randomized (1:1) to once-daily tazarotene 0." | 5.51 | Tazarotene 0.045% Lotion for Females With Acne: Analysis of Two Adult Age Groups. ( Baldwin, H; Callender, V; Cook-Bolden, F; Del Rosso, J; Guenin, E; Kircik, L; Stein Gold, L; Tanghetti, E; Zeichner, J, 2022) |
| "Topical retinoids are the initial treatment for acne due to their ability to treat comedones, the starting point of acne." | 5.43 | Tazarotene foam, 0.1%, for the treatment of acne. ( Feldman, SR; Hill, D; Narahari, S; Smith, JA, 2016) |
| "Patients aged ≥ 9 years with moderate-to-severe acne (score 3 or 4 on the Evaluator's Global Severity Score [EGSS]) were equally randomized to once-daily tazarotene 0." | 5.41 | Tazarotene 0.045% Lotion for Moderate-to-Severe Acne Patients: Pooled Phase 3 Analysis by Age and Sex. ( Del Rosso, JQ; Green, LJ; Guenin, E; Tanghetti, EA, 2021) |
| "In two phase 3 trials (NCT03168334, NCT03168321), participants with moderate-to-severe acne had significant symptom improvements after 12 weeks of treatment with tazarotene 0." | 5.34 | Effects of Tazarotene 0.045% Lotion on Quality of Life in Patients With Moderate-to-Severe Acne. ( Baldwin, H; Gold, M; Guenin, E; Katz, B; Kircik, LH; Lain, E; Loncaric, A; Pillai, R, 2020) |
| "In two phase 3, double-blind, vehicle-controlled 12-week studies, patients with moderate-to-severe acne (N=1,614) were randomized (1:1) to receive tazarotene 0." | 5.34 | New Polymeric Once-Daily Tazarotene 0.045% Lotion Formulation for Moderate-to-Severe Acne: Pooled Phase 3 Pediatric Analysis. ( Eichenfield, LF; Guenin, E; Martin, G; Pillai, R; Tanghetti, EA, 2020) |
| "Background: Tazarotene has been extensively studied in clinical trials and is widely used to treat acne vulgaris (acne)." | 5.30 | A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne Vulgaris ( Green, LJ; Guenin, E; Harris, S; Kircik, LH; Martin, G; Pillai, R; Tanghetti, EA, 2019) |
| "Topical retinoids, such as adapalene gel and tazarotene cream, are considered first-line therapy for the treatment of acne vulgaris." | 5.13 | Is switching retinoids a sound strategy for the treatment of acne vulgaris? ( Colón, LE; Gold, LS; Gottschalk, RW; Johnson, LA, 2008) |
| "Results of clinical trials have shown that tazarotene cream used as monotherapy effectively reduces the number of both inflammatory and noninflammatory lesions in patients with acne vulgaris." | 5.11 | Topical tazarotene: The BEST (balancing efficacy, speed, and tolerability) in acne trial. ( Shalita, A, 2004) |
| "A multicenter, investigator-masked, randomized, parallel-group study was performed in 440 patients with mild-to-moderate facial acne vulgaris to compare the efficacy and tolerability of tazarotene monotherapy with 3 combination regimens--tazarotene plus benzoyl peroxide gel, tazarotene plus erythromycin/benzoyl peroxide gel, and tazarotene plus clindamycin phosphate lotion." | 5.10 | Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. ( Draelos, ZD; Tanghetti, EA, 2002) |
| "To review a decade of experience using tazarotene as a monotherapy or as combination therapy for approved and other indications: acne, psoriasis, photoaging, basal cell carcinomas and various keratinization disorders." | 4.85 | Efficacy and safety of topical tazarotene: a review. ( Cox, K; Duvic, M; Talpur, R, 2009) |
| "Tazarotene is a receptor-selective retinoid, which is efficacious in the treatment of patients with psoriasis, acne vulgaris, and photoaging." | 4.82 | Optimizing treatment with topical tazarotene. ( Guenther, LC, 2003) |
| "Topical tazarotene has shown superior efficacy over other topical retinoids, including adapalene and tretinoin, in the treatment of mild to moderate acne." | 4.82 | Meta-analysis of topical tazarotene in the treatment of mild to moderate acne. ( Leyden, JJ, 2004) |
| "Adapalene (Differin) is a retinoid agent indicated for the topical treatment of acne vulgaris." | 4.82 | Spotlight on adapalene in acne vulgaris. ( Noble, S; Scott, LJ; Waugh, J, 2004) |
| "Tazarotene (AGN 190168) is a new acetylenic retinoid which is effective for the topical treatment of patients with stable plaque psoriasis and mild to moderate acne vulgaris." | 4.80 | Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. ( Matsumoto, RM; Tang-Liu, DD; Usansky, JI, 1999) |
| "Background: As current tazarotene formulations indicated for acne (0." | 3.96 | Novel Polymeric Lotion Formulation of Once-Daily Tazarotene (0.045%) for Moderate-to-Severe Acne: Pooled Phase 3 Analysis. ( Guenin, E; Harris, S; Lain, E; Loncaric, A; Pillai, R; Tanghetti, EA; Werschler, WP, 2020) |
| "The objective of this study was to develop and evaluate a novel microemulsion based gel formulation containing tazarotene for targeted topical therapy of acne." | 3.83 | Novel microemulsion-based gel formulation of tazarotene for therapy of acne. ( Parikh, JR; Patel, BG; Patel, MR; Patel, RB, 2016) |
| "By contrast, median qualitative acne scar scores were the same for both treatment groups at baseline and did not significantly change following either treatment." | 2.90 | Topical Tazarotene Gel, 0.1%, as a Novel Treatment Approach for Atrophic Postacne Scars: A Randomized Active-Controlled Clinical Trial. ( Afra, TP; Dogra, S; Kumar, A; Narang, T; Razmi T, M, 2019) |
| "Retinoids are first-line therapy in the treatment of acne vulgaris." | 2.82 | Tazarotene 0.045% Lotion: A Novel Retinoid Formulation. ( Feldman, SR; Mohney, LA; Singh, R, 2022) |
| "Acne is a multifactorial chronic dermatosis that can be effectively treated with adjuvant medications." | 2.78 | Clindamycin phosphate 1.2%-benzoyl peroxide (5% or 2.5%) plus tazarotene cream 0.1% for the treatment of acne. ( Dhawan, SS; Gwazdauskas, J, 2013) |
| "Tazarotene was approved by U." | 2.75 | Topical tazarotene cream (0.1%) in the treatment of facial acne: an open clinical trial. ( Choudhury, AM; Islam, MT; Paul, HK; Rahman, MA; Zakaria, AS, 2010) |
| "Adapalene gel was associated with fewer treatment-related adverse events than tazarotene cream (36% versus 58%, respectively), and less than half as many adverse events that were "definitely" related to study treatment than tazarotene cream (20% versus 45%, respectively)." | 2.73 | Adapalene 0.1% gel compared to tazarotene 0.1% cream in the treatment of acne vulgaris. ( Colón, LE; Gottschalk, RW; Johnson, LA; Pariser, D, 2008) |
| "The adapalene arm was also therapeutically similar to the tazarotene arm in terms of the percent reduction in inflammatory and noninflammatory lesion counts at week 12, as well as in the assessments of acne severity and improvement." | 2.73 | Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris. ( Arsonnaud, S; Soto, P; Thiboutot, D, 2008) |
| "Two separate, randomised, single-centre, nonblinded, parallel-group pharmacokinetic studies were conducted." | 2.71 | Pharmacokinetics of tazarotene cream 0.1% after a single dose and after repeat topical applications at clinical or exaggerated application rates in patients with acne vulgaris or photodamaged skin. ( Lew-Kaya, D; Sefton, J; Tang-Liu, DD; Walker, P; Yu, D; Yu, Z, 2003) |
| "Tazarotene treatment was associated with a significantly greater incidence of treatment success (defined as > or = 50% global improvement [67% vs 49%; P=." | 2.70 | Once-daily tazarotene 0.1 % gel versus once-daily tretinoin 0.1 % microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial. ( Berson, D; Lee, J; Leyden, JJ; Miller, B; Tanghetti, EA; Ung, M, 2002) |
| "Acne vulgaris is a chronic disfiguring inflammatory disease of adolescents and adults affecting up to 90% of the population around the world." | 2.66 | Selective RAR agonists for acne vulgaris: A narrative review. ( Abdelmaksoud, A; Galadari, H; Goldust, M; Grabbe, S; Gupta, M; Karagaiah, P; Kassir, M; Katsambas, A; Lotti, T; Sonthalia, S; Wollina, U, 2020) |
| "Adapalene/BPO was superior to vehicle counting inflammatory lesions/non-inflammatory lesions (RR 1." | 2.53 | How Much Do We Know about Maintaining Treatment Response after Successful Acne Therapy? Systematic Review on the Efficacy and Safety of Acne Maintenance Therapy. ( Dressler, C; Nast, A; Rosumeck, S, 2016) |
| " Local adverse effects, including erythema, dryness, itching, and stinging, occur frequently during the early treatment phase." | 2.44 | Topical retinoids in acne vulgaris: update on efficacy and safety. ( Gollnick, H; Thielitz, A, 2008) |
| " Limited systemic exposure to the drug also ensures that any adverse effects are local effects rather than systemic effects." | 2.41 | Pharmacokinetics and safety of tazarotene. ( Menter, A, 2000) |
| "Tazarotene is a pro-drug of tazarotenic acid, a receptor-selective retinoid, which has shown efficacy in the treatment of these disorders." | 2.41 | Topical tazarotene therapy for psoriasis, acne vulgaris, and photoaging. ( Guenther, LC, 2002) |
| "Tazarotene 0." | 1.72 | Tazarotene Lotion 0.045% for the Treatment of Acne ( Zip, C, 2022) |
| "Topical retinoids are the initial treatment for acne due to their ability to treat comedones, the starting point of acne." | 1.43 | Tazarotene foam, 0.1%, for the treatment of acne. ( Feldman, SR; Hill, D; Narahari, S; Smith, JA, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (5.41) | 18.2507 |
| 2000's | 35 (47.30) | 29.6817 |
| 2010's | 15 (20.27) | 24.3611 |
| 2020's | 20 (27.03) | 2.80 |
| Authors | Studies |
|---|---|
| Kircik, LH | 6 |
| Green, L | 3 |
| Guenin, E | 13 |
| Khalid, W | 1 |
| Alexander, B | 1 |
| Draelos, ZD | 4 |
| Draelos, MM | 1 |
| Mohney, LA | 1 |
| Singh, R | 1 |
| Feldman, SR | 3 |
| Draelos, Z | 7 |
| Tanghetti, E | 10 |
| Werschler, W | 2 |
| Kircik, L | 7 |
| Angel, A | 1 |
| Lagmay, E | 1 |
| Stein Gold, L | 2 |
| Baldwin, H | 3 |
| Callender, V | 3 |
| Del Rosso, J | 3 |
| Zeichner, J | 2 |
| Cook-Bolden, F | 2 |
| Zip, C | 1 |
| Tyring, S | 1 |
| Issa, N | 2 |
| Tanghetti, EA | 9 |
| Werschler, WP | 2 |
| Lain, T | 1 |
| Martin, G | 3 |
| Pillai, R | 5 |
| Cook-Bolden, FE | 2 |
| Gold, MH | 1 |
| Kassir, M | 1 |
| Karagaiah, P | 1 |
| Sonthalia, S | 1 |
| Katsambas, A | 1 |
| Galadari, H | 1 |
| Gupta, M | 1 |
| Lotti, T | 1 |
| Wollina, U | 1 |
| Abdelmaksoud, A | 1 |
| Grabbe, S | 1 |
| Goldust, M | 1 |
| Gupta, AK | 1 |
| Bruce, A | 1 |
| Abramovits, W | 2 |
| Lain, E | 2 |
| Harris, S | 3 |
| Loncaric, A | 3 |
| Eichenfield, LF | 1 |
| Bhatia, N | 1 |
| Weiss, JS | 1 |
| Sadick, N | 1 |
| Tyring, SK | 1 |
| Gold, LS | 2 |
| Beer, K | 1 |
| Kang, R | 1 |
| Varughese, J | 1 |
| Gold, M | 1 |
| Katz, B | 1 |
| Green, LJ | 2 |
| Del Rosso, JQ | 6 |
| Maiti, R | 1 |
| Sirka, CS | 1 |
| Ashique Rahman, MA | 1 |
| Srinivasan, A | 1 |
| Parida, S | 1 |
| Hota, D | 1 |
| Afra, TP | 1 |
| Razmi T, M | 1 |
| Narang, T | 1 |
| Dogra, S | 1 |
| Kumar, A | 1 |
| Jarratt, M | 1 |
| Werner, CP | 2 |
| Alió Saenz, AB | 2 |
| Dhawan, SS | 1 |
| Gwazdauskas, J | 1 |
| Patel, MR | 1 |
| Patel, RB | 1 |
| Parikh, JR | 1 |
| Patel, BG | 1 |
| Smith, JA | 1 |
| Narahari, S | 1 |
| Hill, D | 1 |
| Dressler, C | 1 |
| Rosumeck, S | 1 |
| Nast, A | 1 |
| Yeh, L | 1 |
| Bonati, LM | 1 |
| Silverberg, NB | 1 |
| Thiboutot, D | 1 |
| Arsonnaud, S | 2 |
| Soto, P | 1 |
| Pariser, D | 1 |
| Colón, LE | 2 |
| Johnson, LA | 2 |
| Gottschalk, RW | 2 |
| Thielitz, A | 1 |
| Gollnick, H | 1 |
| Ghali, F | 1 |
| Kang, S | 1 |
| Leyden, J | 5 |
| Shalita, AR | 4 |
| Thiboutot, DM | 3 |
| Talpur, R | 1 |
| Cox, K | 1 |
| Duvic, M | 1 |
| Dhawan, S | 3 |
| Shalita, A | 3 |
| Glaser, DA | 1 |
| Grimes, P | 2 |
| Webster, G | 2 |
| Barnett, P | 1 |
| Le Gall, N | 1 |
| Zakaria, AS | 1 |
| Paul, HK | 1 |
| Rahman, MA | 1 |
| Islam, MT | 1 |
| Choudhury, AM | 1 |
| Ling, M | 2 |
| Downie, J | 1 |
| Germain, MA | 1 |
| Kasteler, JS | 1 |
| Oefelein, MG | 1 |
| Liao, DC | 1 |
| Guenther, LC | 2 |
| Yu, Z | 1 |
| Sefton, J | 3 |
| Lew-Kaya, D | 1 |
| Walker, P | 1 |
| Yu, D | 1 |
| Tang-Liu, DD | 2 |
| Leyden, JJ | 4 |
| Anderson, DN | 1 |
| Callender, VD | 2 |
| Zane, LT | 1 |
| Waugh, J | 1 |
| Noble, S | 1 |
| Scott, LJ | 1 |
| Berson, DS | 1 |
| Parizadeh, D | 1 |
| Walker, PS | 1 |
| Gibson, JR | 2 |
| Dosik, JS | 1 |
| Homer, K | 1 |
| Solomon, B | 1 |
| Loven, K | 2 |
| Washenik, K | 1 |
| Strober, BE | 1 |
| Shupack, J | 1 |
| Bikowski, J | 1 |
| Torok, H | 1 |
| Chalker, DK | 1 |
| Griffith, RF | 1 |
| Herbert, AA | 1 |
| Hickman, JG | 1 |
| Maloney, JM | 1 |
| Miller, BH | 1 |
| Tschen, EH | 1 |
| Chandraratna, RA | 1 |
| Lew-Kaya, DA | 1 |
| Lue, JC | 1 |
| Matsumoto, RM | 1 |
| Usansky, JI | 1 |
| Menter, A | 1 |
| Kakita, L | 2 |
| Lowe, N | 1 |
| Webster, GF | 2 |
| Berson, D | 2 |
| Stein, LF | 1 |
| Fivenson, DP | 1 |
| Grove, GL | 1 |
| Bershad, S | 2 |
| Kranjac Singer, G | 1 |
| Parente, JE | 1 |
| Tan, MH | 1 |
| Sherer, DW | 1 |
| Persaud, AN | 1 |
| Lebwohl, M | 1 |
| Miller, B | 1 |
| Ung, M | 1 |
| Lee, J | 2 |
| Guenther, L | 1 |
| Poulin, YP | 1 |
| Solomon, BA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Safety and Efficacy of Tazarotene 0.1% Plus Clindamycin 1% Gel vs. Adapalene 0.1% Plus Clindamycin 1% Gel in the Treatment of Facial Acne Vulgaris: A Randomized Controlled Trial[NCT02721173] | Phase 4 | 60 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| Microneedling Versus Topical Tazarotene 0.1% Gel for the Treatment of Atrophic Post Acne Scarring - a Randomized Controlled Study[NCT03170596] | 36 participants (Actual) | Interventional | 2017-06-02 | Completed | |||
| A Single-Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris[NCT01019603] | Phase 1 | 30 participants (Actual) | Interventional | 2009-10-12 | Completed | ||
| A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris[NCT01016977] | Phase 4 | 40 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Acne Vulgaris[NCT01017146] | Phase 3 | 744 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Acne Vulgaris[NCT01017120] | Phase 3 | 742 participants (Actual) | Interventional | 2009-10-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Skindex-29 is a 3-component (symptomatic, emotional, and functional) self-administered questionnaire (comprised of 30 questions) used to comprehensively measure the complex effects of skin diseases on a participant's quality of life. Participants were asked to answer questions based on a 5-point scale concerning their feelings over the past 4 weeks about the skin condition that has bothered them the most: 1, never; 2, rarely; 3, sometimes; 4, often; 5, all the time. The Emotional Score is the sum of 10 question scores; total score ranges from 10 to 50. (NCT01016977)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| Tazorac Cream/Duac Gel | -11.2 |
| Tazorac Cream/Acanya Gel | -7.1 |
Skindex-29 is a 3-component (symptomatic, emotional, and functional) self-administered questionnaire (comprised of 30 questions) used to comprehensively measure the complex effects of skin diseases on a participant's quality of life. Participants were asked to answer questions based on a 5-point scale concerning their feelings over the past 4 weeks about the skin condition that has bothered them the most: 1, never; 2, rarely; 3, sometimes; 4, often; 5, all the time. The Functional Score is the sum of 12 question scores; total score ranges from 12 to 60. (NCT01016977)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| Tazorac Cream/Duac Gel | -6.1 |
| Tazorac Cream/Acanya Gel | -3.7 |
Skindex-29 is a 3-component (symptomatic, emotional, and functional) self-administered questionnaire (comprised of 30 questions) used to comprehensively measure the complex effects of skin diseases on a participant's quality of life. Participants were asked to answer questions based on a 5-point scale concerning their feelings over the past 4 weeks about the skin condition that has bothered them the most: 1, never; 2, rarely; 3, sometimes; 4, often; 5, all the time. The Global Score is the sum of the 30 question scores; total score ranges from 30 to 150. (NCT01016977)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| Tazorac Cream/Duac Gel | -6.1 |
| Tazorac Cream/Acanya Gel | -3.7 |
Skindex-29 is a 3-component (symptomatic, emotional, and functional) self-administered questionnaire (comprised of 30 questions) used to comprehensively measure the complex effects of skin diseases on a participant's quality of life. Participants were asked to answer questions based on a 5-point scale concerning their feelings over the past 4 weeks about the skin condition that has bothered them the most: 1, never; 2, rarely; 3, sometimes; 4, often; 5, all the time. The Symptomatic Score is the sum of 7 question scores; total score ranges from 7 to 35. (NCT01016977)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| Tazorac Cream/Duac Gel | -8.7 |
| Tazorac Cream/Acanya Gel | -1.4 |
The investigator conducted the overall assessment of the participant's facial acne vulgaris based on the Investigator's Static Global Assessment Scale (ISGA). The ISGA is a 6-point scale: 0, clear skin with no acne vulgaris; 1, almost clear skin; 2, mild; 3, moderate; 4, severe; 5, very severe. (NCT01016977)
Timeframe: Baseline and Week 12
| Intervention | participants (Number) |
|---|---|
| Tazorac Cream/Duac Gel | 7 |
| Tazorac Cream/Acanya Gel | 10 |
Mean change from baseline was calculated as the average value at Weeks 1, 2, 4, 8, and 12 minus the value at baseline. Burning/stinging was assessed by participants based on a 6-point scale: 0=none: normal, no discomfort; 1=trace: awareness, no discomfort, no intervention required; 2=mild: noticeable discomfort, intermittent awareness; 3=moderate: noticeable discomfort, continuous awareness; 4=marked: definite discomfort, continuous awareness, interferes occasionally with normal daily activities; 5=severe: definite continuous discomfort, interferes with normal daily activities. (NCT01016977)
Timeframe: Baseline and Weeks 1, 2, 4, 8, and 12
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Week 1, n=19, 17 | Week 2, n=20, 19 | Week 4, n=20, 20 | Week 8, n=20, 20 | Week 12, n=20, 20 | |
| Tazorac Cream/Acanya Gel | 1.65 | 0.84 | 0.55 | 0.45 | 0.40 |
| Tazorac Cream/Duac Gel | 1.58 | 0.70 | 1.25 | 0.60 | 0.50 |
Mean change from baseline was calculated as the average value at Weeks 1, 2, 4, 8, and 12 minus the value at baseline. Dryness was assessed by the investigator based on a 6-point scale: 0=none, which is normal; 1=trace, which is mild and localized; 2=mild, which is mild and diffuse; 3=moderate, which is moderate and diffuse; 4=marked, which is moderate and dense; 5=severe, which is prominent and dense. (NCT01016977)
Timeframe: Baseline and Weeks 1, 2, 4, 8, and 12
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Week 1, n=19, 17 | Week 2, n=20, 19 | Week 4, n=20, 20 | Week 8, n=20, 20 | Week 12, n=20, 20 | |
| Tazorac Cream/Acanya Gel | 1.18 | 0.84 | 0.55 | 0.15 | -0.05 |
| Tazorac Cream/Duac Gel | 1.11 | 1.15 | 0.65 | 0.50 | 0.20 |
Mean change from baseline was calculated as the average value at Weeks 1, 2, 4, 8, and 12 minus the value at baseline. Erythema (redness of the skin, due to increased blood flow in the capillaries in the lower layers of theh skin) was assessed by the investigator based on a 6-point scale: 0=none, which is normal; 1=trace, which is mild and localized; 2=mild, which is mild and diffuse; 3=moderate, which is moderate and diffuse; 4=marked, which is moderate and dense; 5=severe, which is prominent and dense. (NCT01016977)
Timeframe: Baseline and Weeks 1, 2, 4, 8, and 12
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Week 1, n=19, 17 | Week 2, n=20, 19 | Week 4, n=20, 20 | Week 8, n=20, 20 | Week 12, n=20, 20 | |
| Tazorac Cream/Acanya Gel | 0.76 | 0.47 | 0.55 | 0.20 | 0.10 |
| Tazorac Cream/Duac Gel | 0.79 | 0.60 | 0.50 | 0.20 | 0.25 |
Inflammation is defined as a localized protective reaction of tissue to irritation, injury, or infection, characterized by pain, redness, swelling, and sometimes loss of function. The investigator counted inflammatory (papules, pustules, and nodules) and non-inflammatory (open and closed comedones) lesions on a participant's face at each study visit. The face is defined as the hairline edge to the mandibular line and should include the forehead, cheeks, and chin. W, Week. (NCT01016977)
Timeframe: Baseline and Weeks 1, 2, 4, 8, and 12
| Intervention | lesions (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| W1, Inflammatory lesions, n=19, 17 | W2, Inflammatory lesions, n=20, 19 | W4, Inflammatory lesions, n=20, 20 | W8, Inflammatory lesions, n=20, 20 | W12, Inflammatory lesions, n=20, 20 | W1, Non-inflammatory lesions, n=19, 17 | W2, Non-inflammatory lesions, n=20, 19 | W4, Non-inflammatory lesions, n=20, 20 | W8, Non-inflammatory lesions, n=20, 20 | W12, Non-inflammatory lesions, n=20, 20 | |
| Tazorac Cream/Acanya Gel | -5.9 | -8.1 | -9.6 | -16.3 | -13.4 | -7.6 | -15.1 | -26.6 | -33.1 | -37.8 |
| Tazorac Cream/Duac Gel | -6.6 | -8.8 | -13.0 | -14.9 | -18.0 | -3.2 | -17.9 | -23.6 | -28.9 | -32.6 |
Mean change from baseline was calculated as the average value at Weeks 1, 2, 4, 6, 8, and 12 minus the value at baseline. Itching was assessed by participants based on a 6-point scale: 0=none: normal, no discomfort; 1=trace: awareness, no discomfort, no intervention required; 2=mild: noticeable discomfort, intermittent awareness; 3=moderate: noticeable discomfort, continuous awareness; 4=marked: definite discomfort, continuous awareness, interferes occasionally with normal daily activities; 5=severe: definite continuous discomfort, interferes with normal daily activities. (NCT01016977)
Timeframe: Baseline and Weeks 1, 2, 4, 8, and 12
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Week 1, n=19, 17 | Week 2, n=20, 19 | Week 4, n=20, 20 | Week 8, n=20, 20 | Week 12, n=20, 20 | |
| Tazorac Cream/Acanya Gel | 0.76 | 0.84 | 0.65 | 0.30 | 0.45 |
| Tazorac Cream/Duac Gel | 0.68 | 0.10 | 0.20 | -0.05 | 0.35 |
Mean change from baseline was calculated as the average value at Weeks 1, 2, 4, 8, and 12 minus the value at baseline. Oiliness was assessed by participants based on a 6-point scale: 0=none: normal, no discomfort; 1=trace: awareness, no discomfort, no intervention required; 2=mild: noticeable discomfort, intermittent awareness; 3=moderate: noticeable discomfort, continuous awareness; 4=marked: definite discomfort, continuous awareness, interferes occasionally with normal daily activities; 5=severe: definite continuous discomfort, interferes with normal daily activities. (NCT01016977)
Timeframe: Baseline and Weeks 1, 2, 4, 8, and 12
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Week 1, n=19, 17 | Week 2, n=20, 19 | Week 4, n=20, 20 | Week 8, n=20, 20 | Week 12, n=20, 20 | |
| Tazorac Cream/Acanya Gel | -1.29 | -1.05 | -0.55 | -1.05 | -0.75 |
| Tazorac Cream/Duac Gel | -1.00 | -0.95 | -0.85 | -0.80 | -0.35 |
Mean change from baseline was calculated as the average value at Weeks 1, 2, 4, 8, and 12 minus the value at baseline. Peeling was assessed by the investigator based on a 6-point scale: 0=none, which is normal; 1=trace, which is mild and localized; 2=mild, which is mild and diffuse; 3=moderate, which is moderate and diffuse; 4=marked, which is moderate and dense; 5=severe, which is prominent and dense. (NCT01016977)
Timeframe: Baseline and Weeks 1, 2, 4, 8, and 12
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Week 1, n=19, 17 | Week 2, n=20, 19 | Week 4, n=20, 20 | Week 8, n=20, 20 | Week 12, n=20, 20 | |
| Tazorac Cream/Acanya Gel | 1.06 | 0.79 | 0.55 | 0.10 | -0.05 |
| Tazorac Cream/Duac Gel | 1.11 | 1.05 | 0.60 | 0.50 | 0.20 |
Mean change from baseline was calculated as the average value at Weeks 1, 2, 4, 8, and 12 minus the value at baseline. Skin comfort was assessed by participants based on 5-point scale: +2, very comfortable; +1, comfortable; 0, neutral; -1, somewhat uncomfortable; or -2, uncomfortable. (NCT01016977)
Timeframe: Baseline and Weeks 1, 2, 4, 8, and 12
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Week 1, n=19, 17 | Week 2, n=20, 19 | Week 4, n=20, 20 | Week 8, n=20, 20 | Week 12, n=20, 20 | |
| Tazorac Cream/Acanya Gel | -0.29 | 0.05 | -0.10 | 0.10 | 0.60 |
| Tazorac Cream/Duac Gel | -0.37 | 0.25 | 0.05 | 0.30 | 0.45 |
The investigator will count inflammatory (papules, pustules, and nodules) and non-inflammatory (open and closed comedones) lesions on the participant's face at each study visit. The face is defined as the hairline edge to the mandibular line and should include the forehead, cheeks, and chin. (NCT01016977)
Timeframe: Baseline and Weeks 1, 2, 4, 8, and 12
| Intervention | lesions (Mean) | ||||
|---|---|---|---|---|---|
| Week 1, n=19, 17 | Week 2, n=20, 19 | Week 4, n=20, 20 | Week 8, n=20, 20 | Week 12, n=20, 20 | |
| Tazorac Cream/Acanya Gel | -13.5 | -23.1 | -36.2 | -49.4 | -51.1 |
| Tazorac Cream/Duac Gel | -9.8 | -26.6 | -36.6 | -43.7 | -50.6 |
"Overall satisfaction with the study product was assessed from a participant's answer to the following question on the product acceptability and preference questionnaire at the end of study (i.e., Week 12): What is your overall satisfaction with the study product. Participants assessed overall satisfaction with the study product in the morning and evening, based on a 6-point scale: 1, very satisfied; 2, satisfied; 3, neutral (no opinion); 4, unsatisfied; 5, very unsatisfied." (NCT01016977)
Timeframe: Week 12
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Morning | Evening | |
| Tazorac Cream/Acanya Gel | 1.75 | 1.70 |
| Tazorac Cream/Duac Gel | 1.76 | 1.59 |
Investigators evaluated the acne severity (S) of the participants' face using the ISGA scale, ranging from 0 to 5: 0=clear skin with no ILs or NILs; 1=almost clear: rare NIL with no more than rare papules; 2=mild S: >G 1, some NILs with no more than a few ILs (papules/pustules only, no nodular lesions [NLs]); 3=moderate S: >G 2, up to many NILs and may have some ILs, but no more than one small NL; 4=severe: greater than G 3, up to many NILs and ILs, but no more than a few NLs; 5=very severe: many NILs and ILs and more than a few NLs, may have cystic lesions. (NCT01017146)
Timeframe: Baseline (Week 0/Day 1) and Week 12
| Intervention | participants (Number) |
|---|---|
| Tazarotene Foam | 132 |
| Vehicle Foam | 89 |
Investigators evaluated the acne severity (S) of the participants' face using the ISGA scale, ranging from 0 to 5: 0=clear skin with no ILs or NILs; 1=almost clear: rare NIL with no more than rare papules; 2=mild S: >G 1, some NILs with no more than a few ILs (papules/pustules only, no nodular lesions [NLs]); 3=moderate S: >G 2, up to many NILs and may have some ILs, but no more than one small NL; 4=severe: greater than G 3, up to many NILs and ILs, but no more than a few NLs; 5=very severe: many NILs and ILs and more than a few NLs, may have cystic lesions. (NCT01017146)
Timeframe: Week 12
| Intervention | participants (Number) |
|---|---|
| Tazarotene Foam | 107 |
| Vehicle Foam | 60 |
Time to a 50 percent reduction in TLC (sum of ILs and NILs) was the time difference between Baseline and the time to 50 percent reduction in LC. Participants who did not have a >=50 percent reduction from Baseline in TLC during the study were censored at their last visit date. (NCT01017146)
Timeframe: Baseline (Week 0/Day 1) to Week 12
| Intervention | days (Median) |
|---|---|
| Tazarotene Foam | 57 |
| Vehicle Foam | 85 |
LC: count of all ILs (i.e., papules, pustules, and nodules) and NILs (i.e., open and closed comedones) at Baseline and at Week 12. TLs were calculated as the sum of ILs and NILs. LC was confined to the face (including forehead, nose, checks, and chin). Change from Baseline at Week 12 was calculated as the value at Week 12 minus the value at baseline. Calculation was based on last observation carried forward (LOCF) imputation method for missing data. (NCT01017146)
Timeframe: Baseline (Week 0/Day 1); Weeks 2, 4, and 8
| Intervention | lesion counts (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| ILs, Week 2 | ILs, Week 4 | ILs, Week 8 | NILs, Week 2 | NILs, Week 4 | NILs, Week 8 | TLs, Week 2 | TLs, Week 4 | TLs, Week 8 | |
| Tazarotene Foam | -5.5 | -10.1 | -15.6 | -12.6 | -18.2 | -24.6 | -18.1 | -28.3 | -40.1 |
| Vehicle Foam | -6.5 | -10.9 | -13.2 | -8.6 | -12.2 | -14.8 | -15.1 | -23.1 | -27.9 |
LC: count of all inflammatory lesions (ILs, i.e., papules, pustules, and nodules) and non-inflammatory lesions (NILs, i.e., open and closed comedones) at Baseline and at Week 12. Total lesions (TLs) were calculated as the sum of ILs and NILs. LC was confined to the face (including forehead, nose, checks, and chin). Change from Baseline at Week 12 was calculated as the value at Week 12 minus the value at Baseline. (NCT01017146)
Timeframe: Baseline (Week 0/Day 1) and Week 12
| Intervention | lesion counts (Mean) | ||
|---|---|---|---|
| ILs | NILs | TLs | |
| Tazarotene Foam | -18.0 | -27.9 | -45.8 |
| Vehicle Foam | -14.1 | -16.7 | -30.8 |
The CDLQI was used to measure how much the participants' skin problem had affected their life over the last week. The CDLQI total score ranges from 0 to 30: 0-1=no effect at all on the participant's life; 2-6=small effect on the participant's life; 7-12=moderate effect on the participant's life; 13-18=very large effect on the participant's life; 19-30=extremely large effect on the participant's life. A lower score on the CDLQI indicates increased quality of life; therefore, negative changes from Baseline indicate improvements. (NCT01017146)
Timeframe: Baseline (Week 0/Day 1); Weeks 2, 4, 8, and 12
| Intervention | scores on a scale (Mean) | |||
|---|---|---|---|---|
| Week 2, n=162,179 | Week 4, n=153, 180 | Week 8, n=148, 171 | Week 12, n=146, 169 | |
| Tazarotene Foam | 1.1 | -0.6 | -1.2 | -1.7 |
| Vehicle Foam | -1.4 | -1.4 | -1.9 | -2.0 |
The DLQI was used to measure how much the participants' skin problem had affected their life over the last week. The DLQI total score ranges from 0 to 30: 0-1=no effect at all on the participant's life; 2-5=small effect on the participant's life; 6-10=moderate effect on the participant's life; 11-20=very large effect on the participant's life; 21-30=extremely large effect on the participant's life. A lower score on the DLQI indicates increased quality of life; therefore, negative changes from Baseline indicate improvements. (NCT01017146)
Timeframe: Baseline (Week 0/Day 1); Weeks 2, 4, 8, and 12
| Intervention | Scores on a scale (Mean) | |||
|---|---|---|---|---|
| Week 2, n=171,165 | Week 4, n=166, 167 | Week 8, n=160, 155 | Week 12, n=154, 155 | |
| Tazarotene Foam | -0.1 | -1.9 | -2.9 | -3.6 |
| Vehicle Foam | -2.1 | -2.5 | -2.7 | -3.1 |
Investigators evaluated the acne severity (S) of the participants' face using the ISGA scale, ranging from 0 to 5: 0=clear skin with no ILs or NILs; 1=almost clear: rare NIL with no more than rare papules; 2=mild S: >G 1, some NILs with no more than a few ILs (papules/pustules only, no nodular lesions [NLs]); 3=moderate S: >G 2, up to many NILs and may have some ILs, but no more than one small NL; 4=severe: greater than G 3, up to many NILs and ILs, but no more than a few NLs; 5=very severe: many NILs and ILs and more than a few NLs, may have cystic lesions. (NCT01017146)
Timeframe: Baseline (Week 0/Day 1); Weeks 2, 4, and 8
| Intervention | participants (Number) | ||
|---|---|---|---|
| Week 2 | Week 4 | Week 8 | |
| Tazarotene Foam | 10 | 23 | 64 |
| Vehicle Foam | 11 | 29 | 44 |
An SGA of the facial skin, excluding the scalp, was performed by participants using a rating scale of 0 to 4: 0=face is basically free of acne, with only an occasional blackhead (Bh) and/or whitehead (Wh); 1=face has several Bhs and/or Whs and small pimples (P), but there are no tender deep-seated bumps or cysts (DSBCs); 2=face has several to many Bhs and/or Whs and small- to medium-sized P, and may have one DSBC; 3=face has many Bhs and/or Whs, many medium- to large-sized P, and perhaps a few DSBCs; 4=face has Bhs and/or Whs, and several to many medium- to large-sized Ps and DSBCs dominate. (NCT01017146)
Timeframe: Weeks 2, 4, 8, and 12
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Week 2 | Week 4 | Week 8 | Week 12 | |
| Tazarotene Foam | 104 | 143 | 187 | 220 |
| Vehicle Foam | 1 | 130 | 165 | 180 |
Investigators evaluated the acne severity (S) of the participants' face using the ISGA scale, ranging from 0 to 5: 0=clear skin with no ILs or NILs; 1=almost clear: rare NIL with no more than rare papules; 2=mild S: >G 1, some NILs with no more than a few ILs (papules/pustules only, no nodular lesions [NLs]); 3=moderate S: >G 2, up to many NILs and may have some ILs, but no more than one small NL; 4=severe: greater than G 3, up to many NILs and ILs, but no more than a few NLs; 5=very severe: many NILs and ILs and more than a few NLs, may have cystic lesions. (NCT01017146)
Timeframe: Weeks 2, 4, and 8
| Intervention | participants (Number) | ||
|---|---|---|---|
| Week 2 | Week 4 | Week 8 | |
| Tazarotene Foam | 4 | 12 | 40 |
| Vehicle Foam | 1 | 7 | 22 |
Burning/stinging is a pain and burning sensation. Local tolerability assessments were performed by the participant at each study visit based on severity as G0 to G3: G0=none; G1=slight; G2=moderate; G3=strong. Maximum During Treatment is defined as the maximum severity of burning/stinging reported at any time during treatment. (NCT01017146)
Timeframe: Baseline (Week 0/Day 1) to Week 12
| Intervention | participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline, G0 | Baseline, G1 | Baseline, G2 | Baseline, G3 | Baseline, Missing G | MDT, G0 | MDT, G1 | MDT, G2 | MDT, G3 | MDT, Missing G | Week 12, G0 | Week 12, G1 | Week 12, G2 | Week 12, G3 | Week 12, Missing G | |
| Tazarotene Foam | 307 | 34 | 26 | 3 | 2 | 52 | 101 | 122 | 87 | 10 | 179 | 94 | 24 | 7 | 68 |
| Vehicle Foam | 291 | 64 | 15 | 2 | 0 | 137 | 159 | 55 | 11 | 10 | 222 | 94 | 13 | 1 | 42 |
Dryness: skin epidermis that lacks moisture/sebum. Local tolerability assessments were performed by the Investigator at each study visit and were graded based on severity as G0 to G4. G0=absent (none); G1=slight (barely perceptible dryness with no flakes or fissure formation); G2=mild (easily perceptible dryness with no flakes or fissure formation); G3=moderate (easily noted dryness and flakes but no fissure formation); G4=severe (easily noted dryness with flakes and fissure formation). Maximum During Treatment is defined as the maximum severity of drying reported at any time during treatment. (NCT01017146)
Timeframe: Baseline (Week 0/Day 1) to Week 12
| Intervention | participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline, G0 | Baseline, G1 | Baseline, G2 | Baseline, G3 | Baseline, G4 | Baseline, Missing G | MDT, G0 | MDT, G1 | MDT, G2 | MDT, G3 | MDT, G4 | MDT, Missing G | Week 12, G0 | Week 12, G1 | Week 12, G2 | Week 12, G3 | Week 12, G4 | Week 12, Missing G | |
| Tazarotene Foam | 329 | 34 | 6 | 2 | 0 | 1 | 96 | 101 | 90 | 72 | 3 | 10 | 208 | 67 | 22 | 7 | 0 | 68 |
| Vehicle Foam | 327 | 36 | 9 | 0 | 0 | 0 | 222 | 102 | 36 | 2 | 0 | 10 | 292 | 33 | 5 | 0 | 0 | 42 |
Erythema is a skin condition characterized by redness or rash. Local tolerability assessments were performed by the Investigator at each study visit and were graded based on severity as G0 to G4: G0=absent (no redness); G1=slight (faint red or pink coloration, barely perceptible); G2=mild (light red or pink coloration); G3=moderate (medium red coloration); G4=severe (beet red coloration). Maximum During Treatment is defined as the maximum severity of erythema reported at any time during treatment. (NCT01017146)
Timeframe: Baseline (Week 0/Day 1) to Week 12
| Intervention | participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline, G0 | Baseline, G1 | Baseline, G2 | Baseline, G3 | Baseline, G4 | Baseline, Missing G | Maximum During Treatment (MDT), G0 | MDT, G1 | MDT, G2 | MDT, G3 | MDT, G4 | MDT, Missing G | Week 12, G0 | Week 12, G1 | Week 12, G2 | Week 12, G3 | Week 12, G4 | Week 12, Missing G | |
| Tazarotene Foam | 250 | 69 | 45 | 7 | 0 | 1 | 81 | 99 | 115 | 64 | 3 | 10 | 159 | 83 | 50 | 11 | 1 | 68 |
| Vehicle Foam | 242 | 99 | 24 | 7 | 0 | 0 | 133 | 152 | 64 | 13 | 0 | 10 | 216 | 87 | 24 | 3 | 0 | 42 |
Itching is a sensation that causes the desire or reflex to scratch. Local tolerability assessments for itching were performed by the participant at each study visit and were graded based on severity as G0 to G3. G0=none; G1=slight; G2=moderate; G3=strong. Maximum During Treatment is defined as the maximum severity of itching reported at any time during treatment. (NCT01017146)
Timeframe: Baseline (Week 0/Day 1) to Week 12
| Intervention | participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline, G0 | Baseline, G1 | Baseline, G2 | Baseline, G3 | Baseline, Missing G | MDT, G0 | MDT, G1 | MDT, G2 | MDT, G3 | MDT, Missing G | Week 12, G0 | Week 12, G1 | Week 12, G2 | Week 12, G3 | Week 12, Missing G | |
| Tazarotene Foam | 237 | 104 | 26 | 3 | 2 | 68 | 164 | 92 | 38 | 10 | 174 | 111 | 17 | 2 | 68 |
| Vehicle Foam | 229 | 109 | 30 | 4 | 0 | 126 | 182 | 48 | 6 | 10 | 216 | 96 | 16 | 2 | 42 |
Peeling skin: damage to and loss of the upper layer of skin (epidermis). Local tolerability assessments for peeling were performed by the Investigator at each study visit and were graded based on severity as G0 to G4: G0=absent (no peeling); G1=slight (mild localized peeling); G2=mild (mild and diffuse peeling); G3=moderate (moderate and diffuse peeling); G4=severe (moderate to prominent, dense peeling). Maximum During Treatment is defined as the maximum severity of peeling reported at any time during treatment. (NCT01017146)
Timeframe: Baseline (Week 0/Day 1) to Week 12
| Intervention | participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline, G0 | Baseline, G1 | Baseline, G2 | Baseline, G3 | Baseline, G4 | Baseline, Missing G | MDT, G0 | MDT, G1 | MDT, G2 | MDT, G3 | MDT, G4 | MDT, Missing G | Week 12, G0 | Week 12, G1 | Week 12, G2 | Week 12, G3 | Week 12, G4 | Week 12, Missing G | |
| Tazarotene Foam | 344 | 22 | 5 | 0 | 0 | 1 | 112 | 104 | 87 | 51 | 8 | 10 | 221 | 57 | 16 | 10 | 0 | 68 |
| Vehicle Foam | 339 | 29 | 4 | 0 | 0 | 0 | 256 | 76 | 28 | 2 | 0 | 10 | 300 | 25 | 5 | 0 | 0 | 42 |
LC: count of all ILs (i.e., papules, pustules, and nodules) and NILs (i.e., open and closed comedones) at Baseline and at Week 12. TLs were calculated as the sum of ILs and NILs. LC was confined to the face (including forehead, nose, checks, and chin). Percent change from Baseline in LC at Weeks 2, 4, 8, and12 was calculated as the (Week 2/4/8/12 value minus the baseline value divided by baseline value) x 100. (NCT01017146)
Timeframe: Baseline (Week 0/Day 1); Weeks 2, 4, 8, and 12
| Intervention | percent change (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ILs, Week 2 | ILs, Week 4 | ILs, Week 8 | ILs, Week 12 | NILs, Week 2 | NILs, Week 4 | NILs, Week 8 | NILs, Week 12 | TLs, Week 2 | TLs, Week 4 | TLs, Week 8 | TLs, Week 12 | |
| Tazarotene Foam | -18.2 | -33.0 | -50.1 | -57.5 | -24.5 | -36.6 | -48.7 | -55.1 | -22.5 | -35.3 | -49.5 | -56.3 |
| Vehicle Foam | -20.9 | -24.8 | -42.1 | -45.2 | -16.6 | -25.0 | -30.6 | -34.3 | -18.8 | -29.3 | -35.6 | -39.0 |
Investigators evaluated the acne severity (S) of the participants' face using the ISGA scale, ranging from 0 to 5: 0=clear skin with no ILs or NILs; 1=almost clear: rare NIL with no more than rare papules; 2=mild S: >G 1, some NILs with no more than a few ILs (papules/pustules only, no nodular lesions [NLs]); 3=moderate S: >G 2, up to many NILs and may have some ILs, but no more than one small NL; 4=severe: greater than G 3, up to many NILs and ILs, but no more than a few NLs; 5=very severe: many NILs and ILs and more than a few NLs, may have cystic lesions. (NCT01017120)
Timeframe: Baseline (Week 0/Day 1) and Week 12
| Intervention | participants (Number) |
|---|---|
| Tazarotene Foam | 120 |
| Vehicle Foam | 67 |
Investigators evaluated the acne severity (S) of the participants' face using the ISGA scale, ranging from 0 to 5: 0=clear skin with no ILs or NILs; 1=almost clear: rare NIL with no more than rare papules; 2=mild S: >G 1, some NILs with no more than a few ILs (papules/pustules only, no nodular lesions [NLs]); 3=moderate S: >G 2, up to many NILs and may have some ILs, but no more than one small NL; 4=severe: greater than G 3, up to many NILs and ILs, but no more than a few NLs; 5=very severe: many NILs and ILs and more than a few NLs, may have cystic lesions. (NCT01017120)
Timeframe: Week 12
| Intervention | participants (Number) |
|---|---|
| Tazarotene Foam | 103 |
| Vehicle Foam | 49 |
Time to a 50 percent reduction in TLC (sum of ILs and NILs) was the time difference between Baseline and the time to 50 percent reduction in LC. Participants who did not have a >=50 percent reduction from Baseline in TLC during the study were censored at their last visit date. (NCT01017120)
Timeframe: Baseline (Week 0/Day 1) to Week 12
| Intervention | days (Median) |
|---|---|
| Tazarotene Foam | 57 |
| Vehicle Foam | 85 |
LC: count of all ILs (i.e., papules, pustules, and nodules) and NILs (i.e., open and closed comedones) at Baseline and at Week 12. TLs were calculated as the sum of ILs and NILs. LC was confined to the face (including forehead, nose, checks, and chin). Change from Baseline at Week 12 was calculated as the value at Week 12 minus the value at Baseline. Calculation was based on last observation carried forward (LOCF) imputation method for missing data. (NCT01017120)
Timeframe: Baseline (Week 0/Day 1); Weeks 2, 4, and 8
| Intervention | lesion counts (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| ILs, Week 2 | ILs, Week 4 | ILs, Week 8 | NILs, Week 2 | NILs, Week 4 | NILs, Week 8 | TLs, Week 2 | TLs, Week 4 | TLs, Week 8 | |
| Tazarotene Foam | -5.9 | -10.7 | -15.7 | -10.7 | -17.3 | -22.6 | -16.6 | -28.0 | -38.3 |
| Vehicle Foam | -5.6 | -10.2 | -13.3 | -7.7 | -11.8 | -16.5 | -13.3 | -22.0 | -29.7 |
A closed comedone is a whitehead. Change from basline in closed comedone count at Weeks 2, 4, 8, and 12 was calculated as the closed comedone count at Week 2/4/8/12 minus the closed comedone count at Baseline. (NCT01017120)
Timeframe: Baseline (Week 0/Day 1); Weeks 2, 4, 8, and 12
| Intervention | closed comedone count (Mean) | |||
|---|---|---|---|---|
| Week 2 | Week 4 | Week 8 | Week 12 | |
| Tazarotene Foam | -7.3 | -11.5 | -15.3 | -17.2 |
| Vehicle Foam | -4.5 | -7.6 | -10.7 | -11.4 |
LC: count of all inflammatory lesions (ILs, i.e., papules, pustules, and nodules) and non-inflammatory lesions (NILs, i.e., open and closed comedones) at Baseline and at Week 12. Total lesions (TLs) were calculated as the sum of ILs and NILs. LC was confined to the face (including forehead, nose, checks, and chin). Change from Baseline at Week 12 was calculated as the value at Week 12 minus the value at Baseline. (NCT01017120)
Timeframe: Baseline (Week 0/Day 1) and Week 12
| Intervention | lesion counts (Mean) | ||
|---|---|---|---|
| ILs | NILs | TLs | |
| Tazarotene Foam | -17.8 | -25.6 | -43.4 |
| Vehicle Foam | -14.7 | -18.2 | -32.9 |
A nodule is a slightly elevated lesion on or in the skin. Change from basline in nodule count at Weeks 2, 4, 8, and 12 was calculated as the nodule count at Week 2/4/8/12 value (s) minus the nodule count at Baseline. (NCT01017120)
Timeframe: Baseline (Week 0/Day 1); Weeks 2, 4, 8, and 12
| Intervention | nodule count (Mean) | |||
|---|---|---|---|---|
| Week 2 | Week 4 | Week 8 | Week 12 | |
| Tazarotene Foam | -0.0 | -0.0 | -0.0 | -0.0 |
| Vehicle Foam | 0.0 | 0.0 | 0.1 | 0.0 |
An open comedone is a yellow or blackish bump or plug on the skin. Change from Baseline in open comedone count at Weeks 2, 4, 8, and 12 was calculated as the open comedone count at Week 2/4/8/12 minus the open comedone count at Baseline. (NCT01017120)
Timeframe: Baseline (Week 0/Day 1); Weeks 2, 4, 8, and 12
| Intervention | open comedone count (Mean) | |||
|---|---|---|---|---|
| Week 2 | Week 4 | Week 8 | Week 12 | |
| Tazarotene Foam | -3.5 | -5.8 | -7.3 | -8.4 |
| Vehicle Foam | -3.1 | -4.2 | -5.8 | -6.9 |
A papule is a circumscribed, solid elevation of the skin with no visible fluid. Change from basline in papule count at Weeks 2, 4, 8, and 12 was calculated as the papule count at Week 2/4/8/12 minus the papule count at Baseline. (NCT01017120)
Timeframe: Baseline (Week 0/Day 1); Weeks 2, 4, 8, and 12
| Intervention | papule count (Mean) | |||
|---|---|---|---|---|
| Week 2 | Week 4 | Week 8 | Week 12 | |
| Tazarotene Foam | -4.3 | -8.3 | -12.0 | -13.5 |
| Vehicle Foam | -4.3 | -7.8 | -10.4 | -11.5 |
A pustule is a small elevation of the skin containing cloudy or purulent material usually consisting of necrotic inflammatory cells. Change from basline in pustule count at Weeks 2, 4, 8, and 12 was calculated as the pustule count at Week 2/4/8/12 minus the pustule count at Baseline. (NCT01017120)
Timeframe: Baseline (Week 0/Day 1); Weeks 2, 4, 8, and 12
| Intervention | pustule count (Mean) | |||
|---|---|---|---|---|
| Week 2 | Week 4 | Week 8 | Week 12 | |
| Tazarotene Foam | -1.5 | -2.4 | -3.7 | -4.2 |
| Vehicle Foam | -1.3 | -2.4 | -2.9 | -3.2 |
The CDLQI was used to measure how much the participants' skin problem had affected their life over the last week. The CDLQI total score ranges from 0 to 30: 0-1=no effect at all on the participant's life; 2-6=small effect on the participant's life; 7-12=moderate effect on the participant's life; 13-18=very large effect on the participant's life; 19-30=extremely large effect on the participant's life. A lower score on the CDLQI indicates increased quality of life; therefore, negative changes from Baseline indicate improvements. (NCT01017120)
Timeframe: Baseline (Week 0/Day 1); Week 2, 4, 8, and 12
| Intervention | scores on a scale (Mean) | |||
|---|---|---|---|---|
| Week 2, n=153, 163 | Week 4, n=143, 158 | Week 8, n=137, 158 | Week 12, n=137, 153 | |
| Tazarotene Foam | 1.3 | -0.9 | -1.6 | -1.6 |
| Vehicle Foam | -1.5 | -1.9 | -1.9 | -2.0 |
The DLQI was used to measure how much the participants' skin problem had affected their life over the last week. The DLQI total score ranges from 0 to 30: 0-1=no effect at all on the participant's life; 2-5=small effect on the participant's life; 6-10=moderate effect on the participant's life; 11-20=very large effect on the participant's life; 21-30=extremely large effect on the participant's life. A lower score on the DLQI indicates increased quality of life; therefore, negative changes from Baseline indicate improvements. (NCT01017120)
Timeframe: Baseline (Week 0/Day 1); Weeks 2, 4, 8, and 12
| Intervention | scores on a scale (Mean) | |||
|---|---|---|---|---|
| Week 2, n=175, 178 | Week 4, n=170, 184 | Week 8, n=163, 176 | Week 12, n=162, 176 | |
| Tazarotene Foam | -1.3 | -2.4 | -2.9 | -3.7 |
| Vehicle Foam | -1.9 | -2.7 | -3.1 | -3.2 |
Investigators evaluated the acne severity (S) of the participants' face using the ISGA scale, ranging from 0 to 5: 0=clear skin with no ILs or NILs; 1=almost clear: rare NIL with no more than rare papules; 2=mild S: >G 1, some NILs with no more than a few ILs (papules/pustules only, no nodular lesions [NLs]); 3=moderate S: >G 2, up to many NILs and may have some ILs, but no more than one small NL; 4=severe: greater than G 3, up to many NILs and ILs, but no more than a few NLs; 5=very severe: many NILs and ILs and more than a few NLs, may have cystic lesions. (NCT01017120)
Timeframe: Baseline (Week 0/Day 1); Weeks 2, 4, 8, and 12
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Week 2 | Week 4 | Week 8 | Week 12 | |
| Tazarotene Foam | 5 | 26 | 56 | 103 |
| Vehicle Foam | 2 | 12 | 26 | 49 |
Investigators evaluated the acne severity (S) of the participants' face using the ISGA scale, ranging from 0 to 5: 0=clear skin with no ILs or NILs; 1=almost clear: rare NIL with no more than rare papules; 2=mild S: >G 1, some NILs with no more than a few ILs (papules/pustules only, no nodular lesions [NLs]); 3=moderate S: >G 2, up to many NILs and may have some ILs, but no more than one small NL; 4=severe: greater than G 3, up to many NILs and ILs, but no more than a few NLs; 5=very severe: many NILs and ILs and more than a few NLs, may have cystic lesions. (NCT01017120)
Timeframe: Baseline (Week 0/Day 1); Weeks 2, 4, and 8
| Intervention | participants (Number) | ||
|---|---|---|---|
| Week 2 | Week 4 | Week 8 | |
| Tazarotene Foam | 8 | 33 | 69 |
| Vehicle Foam | 4 | 16 | 35 |
An SGA of the facial skin, excluding the scalp, was performed by participants using a rating scale of 0 to 4: 0=face is basically free of acne, with only an occasional blackhead (Bh) and/or whitehead (Wh); 1=face has several Bhs and/or Whs and small pimples (P), but there are no tender deep-seated bumps or cysts (DSBCs); 2=face has several to many Bhs and/or Whs and small- to medium-sized P, and may have one DSBC; 3=face has many Bhs and/or Whs, many medium- to large-sized P, and perhaps a few DSBCs; 4=face has Bhs and/or Whs, and several to many medium- to large-sized Ps and DSBCs dominate. (NCT01017120)
Timeframe: Weeks 2, 4, 8, and 12
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Week 2 | Week 4 | Week 8 | Week 12 | |
| Tazarotene Foam | 83 | 136 | 171 | 213 |
| Vehicle Foam | 93 | 114 | 125 | 153 |
Investigators evaluated the acne severity (S) of the participants' face using the ISGA scale, ranging from 0 to 5: 0=clear skin with no ILs or NILs; 1=almost clear: rare NIL with no more than rare papules; 2=mild S: >G 1, some NILs with no more than a few ILs (papules/pustules only, no nodular lesions [NLs]); 3=moderate S: >G 2, up to many NILs and may have some ILs, but no more than one small NL; 4=severe: greater than G 3, up to many NILs and ILs, but no more than a few NLs; 5=very severe: many NILs and ILs and more than a few NLs, may have cystic lesions. (NCT01017120)
Timeframe: Weeks 2, 4, and 8
| Intervention | participants (Number) | ||
|---|---|---|---|
| Week 2 | Week 4 | Week 8 | |
| Tazarotene Foam | 5 | 26 | 56 |
| Vehicle Foam | 2 | 12 | 26 |
Burning/stinging is a pain and burning sensation. Local tolerability assessments were performed by the participant at each study visit based on severity as G0 to G3: G0=none; G1=slight; G2=moderate; G3=strong. Maximum During Treatment is defined as the maximum severity of burning/stinging reported at any time during treatment. (NCT01017120)
Timeframe: Baseline (Week 0/Day 1) to Week 12
| Intervention | participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline, G0 | Baseline, G1 | Baseline, G2 | Baseline, G3 | Baseline, Missing G | MDT, G0 | MDT, G1 | MDT, G2 | MDT, G3 | MDT, Missing G | Week 12, G0 | Week 12, G1 | Week 12, G2 | Week 12, G3 | Week 12, Missing G | |
| Tazarotene Foam | 299 | 60 | 12 | 2 | 0 | 57 | 169 | 105 | 104 | 12 | 168 | 97 | 34 | 8 | 66 |
| Vehicle Foam | 290 | 62 | 16 | 1 | 0 | 109 | 181 | 55 | 16 | 8 | 223 | 86 | 15 | 7 | 38 |
Dryness=skin epidermis that lacks moisture/sebum. Local tolerability assessments were performed by the Investigator at each study visit and were graded based on severity as G0 to G4. G0=absent (none); G1=slight (barely perceptible dryness with no flakes or fissure formation); G2=mild (easily perceptible dryness with no flakes or fissure formation); G3=moderate (easily noted dryness and flakes but no fissure formation); G4=severe (easily noted dryness with flakes and fissure formation). Maximum During Treatment is defined as the maximum severity of dryness reported at any time during treatment. (NCT01017120)
Timeframe: Baseline (Week 0/Day 1) to Week 12
| Intervention | participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline, G0 | Baseline, G1 | Baseline, G2 | Baseline, G3 | Baseline, G4 | Baseline, Missing G | MDT, G0 | MDT, G1 | MDT, G2 | MDT, G3 | MDT, G4 | MDT, Missing G | Week 12, G0 | Week 12, G1 | Week 12, G2 | Week 12, G3 | Week 12, G4 | Week 12, Missing G | |
| Tazarotene Foam | 316 | 39 | 13 | 5 | 0 | 0 | 73 | 136 | 87 | 61 | 5 | 11 | 219 | 73 | 14 | 1 | 0 | 66 |
| Vehicle Foam | 312 | 43 | 8 | 6 | 0 | 0 | 193 | 124 | 36 | 7 | 1 | 8 | 294 | 35 | 2 | 0 | 0 | 38 |
Erythema is a skin condition characterized by redness or rash. Local tolerability assessments were performed by the Investigator at each study visit and were graded based on severity as G0 to G4: G0=absent (no redness); G1=slight (faint red or pink coloration, barely perceptible); G2=mild (light red or pink coloration); G3=moderate (medium red coloration); G4=severe (beet red coloration). Maximum During Treatment is defined as the maximum severity of erythema reported at any time during treatment. (NCT01017120)
Timeframe: Baseline (Week 0/Day 1) to Week 12
| Intervention | participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline, G0 | Baseline, G1 | Baseline, G2 | Baseline, G3 | Baseline, G4 | Baseline, Missing G | Maximum During Treatment (MDT), G0 | MDT, G1 | MDT, G2 | MDT, G3 | MDT, G4 | MDT, Missing G | Week 12, G0 | Week 12, G1 | Week 12, G2 | Week 12, G3 | Week 12, G4 | Week 12, Missing G | |
| Tazarotene Foam | 247 | 65 | 21 | 40 | 0 | 0 | 76 | 117 | 111 | 56 | 2 | 11 | 175 | 93 | 30 | 9 | 0 | 66 |
| Vehicle Foam | 234 | 75 | 20 | 40 | 0 | 0 | 141 | 132 | 51 | 37 | 0 | 8 | 218 | 73 | 21 | 19 | 0 | 38 |
Itching is a sensation that causes the desire or reflex to scratch. Local tolerability assessments for itching were performed by the participant at each study visit and were graded based on severity as G0 to G3. G0=none; G1=slight; G2=moderate; G3=strong. Maximum During Treatment is defined as the maximum severity of itching reported at any time during treatment. (NCT01017120)
Timeframe: Baseline (Week 0/Day 1) to Week 12
| Intervention | participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline, G0 | Baseline, G1 | Baseline, G2 | Baseline, G3 | Baseline, Missing G | MDT, G0 | MDT, G1 | MDT, G2 | MDT, G3 | MDT, Missing G | Week 12, G0 | Week 12, G1 | Week 12, G2 | Week 12, G3 | Week 12, Missing G | |
| Tazarotene Foam | 205 | 133 | 31 | 4 | 0 | 57 | 169 | 96 | 39 | 12 | 176 | 105 | 22 | 4 | 66 |
| Vehicle Foam | 209 | 131 | 27 | 2 | 0 | 145 | 155 | 51 | 10 | 8 | 224 | 88 | 13 | 6 | 38 |
Peeling skin: damage to and loss of the upper layer of skin (epidermis). Local tolerability assessments for peeling were performed by the Investigator at each study visit and were graded based on severity as G0 to G4: G0=absent (no peeling); G1=slight (mild localized peeling); G2=mild (mild and diffuse peeling); G3=moderate (moderate and diffuse peeling); G4=severe (moderate to prominent, dense peeling). Maximum During Treatment is defined as the maximum severity of peeling reported at any time during treatment. (NCT01017120)
Timeframe: Baseline (Week 0/Day 1) to Week 12
| Intervention | participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline, G0 | Baseline, G1 | Baseline, G2 | Baseline, G3 | Baseline, G4 | Baseline, Missing G | MDT, G0 | MDT, G1 | MDT, G2 | MDT, G3 | MDT, G4 | MDT, Missing G | Week 12, G0 | Week 12, G1 | Week 12, G2 | Week 12, G3 | Week 12, G4 | Week 12, Missing G | |
| Tazarotene Foam | 342 | 22 | 7 | 2 | 0 | 0 | 108 | 152 | 69 | 28 | 5 | 11 | 251 | 48 | 7 | 1 | 0 | 66 |
| Vehicle Foam | 339 | 18 | 6 | 6 | 0 | 0 | 255 | 85 | 18 | 3 | 0 | 8 | 313 | 17 | 1 | 0 | 0 | 38 |
LC: count of all ILs (i.e., papules, pustules, and nodules) and NILs (i.e., open and closed comedones) at Baseline and at Week 12. TLs were calculated as the sum of ILs and NILs. LC was confined to the face (including forehead, nose, checks, and chin). Percent change from Baseline in LC at Weeks 2, 4, 8, and12 was calculated as the (Week 2/4/8/12 value minus the baseline value divided by baseline value) x 100. (NCT01017120)
Timeframe: Baseline (Week 0/Day 1); Weeks 2, 4, 8, and 12
| Intervention | percentage change (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ILs, Week 2 | ILs, Week 4 | ILs, Week 8 | ILs, Week 12 | NILs, Week 2 | NILs, Week 4 | NILs, Week 8 | NILs, Week 12 | TLs, Week 2 | TLs, Week 4 | TLs, Week 8 | TLs, Week 12 | |
| Tazarotene Foam | -18.2 | -32.9 | -48.1 | -54.5 | -23.7 | -39.2 | -50.6 | -56.7 | -21.6 | -36.8 | -49.7 | -56.0 |
| Vehicle Foam | -17.4 | -31.4 | -41.0 | -45.3 | -17.3 | -27.3 | -36.6 | -41.2 | -17.1 | -28.9 | -38.4 | -42.6 |
18 reviews available for tazarotene and Acne
| Article | Year |
|---|---|
Tazarotene 0.045% Lotion: A Novel Retinoid Formulation.
Topics: Acne Vulgaris; Administration, Cutaneous; Clinical Trials, Phase III as Topic; Humans; Nicotinic Aci | 2022 |
SUPPLEMENT INDIVIDUAL ARTICLES: Update on Truncal Acne: A Review of Treatments for a Neglected Disease and the Re-Emergence of Tazarotene.
Topics: Acne Vulgaris; Dermatologic Agents; Humans; Neglected Diseases; Retinoids | 2022 |
SUPPLEMENT INDIVIDUAL ARTICLES: Update on Truncal Acne: A Review of Treatments for a Neglected Disease and the Re-Emergence of Tazarotene.
Topics: Acne Vulgaris; Dermatologic Agents; Humans; Neglected Diseases; Retinoids | 2022 |
SUPPLEMENT INDIVIDUAL ARTICLES: Update on Truncal Acne: A Review of Treatments for a Neglected Disease and the Re-Emergence of Tazarotene.
Topics: Acne Vulgaris; Dermatologic Agents; Humans; Neglected Diseases; Retinoids | 2022 |
SUPPLEMENT INDIVIDUAL ARTICLES: Update on Truncal Acne: A Review of Treatments for a Neglected Disease and the Re-Emergence of Tazarotene.
Topics: Acne Vulgaris; Dermatologic Agents; Humans; Neglected Diseases; Retinoids | 2022 |
Selective RAR agonists for acne vulgaris: A narrative review.
Topics: Acne Vulgaris; Adapalene; Administration, Cutaneous; Dermatologic Agents; Humans; Nicotinic Acids; R | 2020 |
How Much Do We Know about Maintaining Treatment Response after Successful Acne Therapy? Systematic Review on the Efficacy and Safety of Acne Maintenance Therapy.
Topics: Acne Vulgaris; Adapalene; Administration, Cutaneous; Benzoyl Peroxide; Dermatologic Agents; Gels; Hu | 2016 |
Topical retinoids in acne vulgaris: update on efficacy and safety.
Topics: Acne Vulgaris; Adapalene; Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Drug The | 2008 |
Changing the face of acne therapy.
Topics: Acne Vulgaris; Adapalene; Administration, Cutaneous; Age Factors; Clinical Protocols; Dermatologic A | 2009 |
Efficacy and safety of topical tazarotene: a review.
Topics: Acne Vulgaris; Administration, Cutaneous; Animals; Carcinoma, Basal Cell; Dermatologic Agents; Human | 2009 |
Management of acne.
Topics: Acne Vulgaris; Adapalene; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial | 2003 |
Optimizing treatment with topical tazarotene.
Topics: Acne Vulgaris; Administration, Topical; Adrenal Cortex Hormones; Calcitriol; Dose-Response Relations | 2003 |
Topical retinoids in the management of acne: the best path to clear results.
Topics: Acne Vulgaris; Adapalene; Dermatologic Agents; Humans; Keratolytic Agents; Meta-Analysis as Topic; M | 2004 |
Meta-analysis of topical tazarotene in the treatment of mild to moderate acne.
Topics: Acne Vulgaris; Adapalene; Administration, Cutaneous; Adult; Dermatologic Agents; Drug Administration | 2004 |
Spotlight on adapalene in acne vulgaris.
Topics: Acne Vulgaris; Adapalene; Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Dermat | 2004 |
Topical treatment of acne vulgaris: retinoids and cutaneous irritation.
Topics: Acne Vulgaris; Adapalene; Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Gels; Hu | 1998 |
Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis.
Topics: Acne Vulgaris; Administration, Topical; Animals; Clinical Trials as Topic; Dermatologic Agents; Huma | 1999 |
Pharmacokinetics and safety of tazarotene.
Topics: Acne Vulgaris; Biological Availability; Biotransformation; Dose-Response Relationship, Drug; Humans; | 2000 |
Tazarotene versus tretinoin or adapalene in the treatment of acne vulgaris.
Topics: Acne Vulgaris; Adapalene; Administration, Topical; Dermatologic Agents; Double-Blind Method; Gels; K | 2000 |
Developments in topical retinoid therapy for acne.
Topics: Acne Vulgaris; Adapalene; Dermatologic Agents; Drug Combinations; Humans; Keratolytic Agents; Naphth | 2001 |
Topical tazarotene therapy for psoriasis, acne vulgaris, and photoaging.
Topics: Acne Vulgaris; Administration, Topical; Humans; Nicotinic Acids; Psoriasis; Retinoids; Skin Aging | 2002 |
39 trials available for tazarotene and Acne
| Article | Year |
|---|---|
Dermal sensitization, safety, tolerability, and patient preference of tazarotene 0.045% lotion from five clinical trials.
Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Dermatologic Agents; Double-Blind Metho | 2022 |
Tazarotene 0.045% Lotion for Females With Acne: Analysis of Two Adult Age Groups.
Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Child; Dermatologic Agents; Double-Blin | 2022 |
Efficacy and Safety of Tazarotene 0.045% Lotion in Caucasian Adults With Moderate-to-Severe Acne.
Topics: Acne Vulgaris; Administration, Cutaneous; Adult; Dermatologic Agents; Double-Blind Method; Emollient | 2022 |
Low irritation potential of tazarotene 0.045% lotion: Head-to-head comparison to adapalene 0.3% gel and trifarotene 0.005% cream in two studies.
Topics: Acne Vulgaris; Adapalene; Adult; Dermatologic Agents; Double-Blind Method; Emollients; Humans; Napht | 2023 |
Tazarotene 0.045% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Results from Two Phase 3 Trials
Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Child; Dermatologic Agents; Double-Blin | 2020 |
Tazarotene 0.045% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Adult Males
Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Age Factors; Child; Dermatologic Agents | 2020 |
New Polymeric Once-Daily Tazarotene 0.045% Lotion Formulation for Moderate-to-Severe Acne: Pooled Phase 3 Pediatric Analysis.
Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Child; Drug Administration Schedule; Female; H | 2020 |
Novel Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Race/Ethnicity.
Topics: Acne Vulgaris; Administration, Cutaneous; Child; Double-Blind Method; Ethnicity; Female; Humans; Ker | 2020 |
Once-Daily Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Sex.
Topics: Acne Vulgaris; Adolescent; Adult; Child; Double-Blind Method; Drug Administration Schedule; Female; | 2020 |
Effects of Tazarotene 0.045% Lotion on Quality of Life in Patients With Moderate-to-Severe Acne.
Topics: Acne Vulgaris; Administration, Cutaneous; Double-Blind Method; Drug Administration Schedule; Female; | 2020 |
Tazarotene 0.045% Lotion for Moderate-to-Severe Acne Patients: Pooled Phase 3 Analysis by Age and Sex.
Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Dermatologic Agents; Double-Blind Metho | 2021 |
Efficacy and Safety of Tazarotene 0.1% Plus Clindamycin 1% Gel Versus Adapalene 0.1% Plus Clindamycin 1% Gel in Facial Acne Vulgaris: A Randomized, Controlled Clinical Trial.
Topics: Acne Vulgaris; Adapalene; Adolescent; Adult; Anti-Bacterial Agents; Clindamycin; Dermatologic Agents | 2017 |
Topical Tazarotene Gel, 0.1%, as a Novel Treatment Approach for Atrophic Postacne Scars: A Randomized Active-Controlled Clinical Trial.
Topics: Acne Vulgaris; Administration, Topical; Adult; Atrophy; Cicatrix; Cosmetic Techniques; Dermatologic | 2019 |
A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne Vulgaris
Topics: Acne Vulgaris; Adolescent; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Emulsions; | 2019 |
Tazarotene foam versus tazarotene gel: a randomized relative bioavailability study in acne vulgaris.
Topics: Acne Vulgaris; Adult; Area Under Curve; Dermatologic Agents; Dosage Forms; Female; Humans; Male; Nic | 2013 |
Clindamycin phosphate 1.2%-benzoyl peroxide (5% or 2.5%) plus tazarotene cream 0.1% for the treatment of acne.
Topics: Acne Vulgaris; Administration, Topical; Adolescent; Adult; Benzoyl Peroxide; Chi-Square Distribution | 2013 |
The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies.
Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Canada; Child; Dermatologic Agents; Dou | 2013 |
The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies.
Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Canada; Child; Dermatologic Agents; Dou | 2013 |
The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies.
Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Canada; Child; Dermatologic Agents; Dou | 2013 |
The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies.
Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Canada; Child; Dermatologic Agents; Dou | 2013 |
The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies.
Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Canada; Child; Dermatologic Agents; Dou | 2013 |
The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies.
Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Canada; Child; Dermatologic Agents; Dou | 2013 |
The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies.
Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Canada; Child; Dermatologic Agents; Dou | 2013 |
The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies.
Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Canada; Child; Dermatologic Agents; Dou | 2013 |
The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies.
Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Canada; Child; Dermatologic Agents; Dou | 2013 |
Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris.
Topics: Acne Vulgaris; Adapalene; Administration, Topical; Adolescent; Adult; Child; Dermatologic Agents; Do | 2008 |
Adapalene 0.1% gel compared to tazarotene 0.1% cream in the treatment of acne vulgaris.
Topics: Acne Vulgaris; Adapalene; Adolescent; Adult; Child; Dermatologic Agents; Double-Blind Method; Erythe | 2008 |
Is switching retinoids a sound strategy for the treatment of acne vulgaris?
Topics: Acne Vulgaris; Adapalene; Administration, Topical; Adolescent; Adult; Child; Dermatologic Agents; Do | 2008 |
Tretinoin microsphere gel pump 0.04% versus tazarotene cream 0.05% in the treatment of mild-to-moderate facial acne vulgaris.
Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Child; Female; Gels; Humans; Keratolyti | 2009 |
Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris.
Topics: Acne Vulgaris; Adapalene; Administration, Cutaneous; Adolescent; Adult; Child; Dermatologic Agents; | 2010 |
Topical tazarotene cream (0.1%) in the treatment of facial acne: an open clinical trial.
Topics: Acne Vulgaris; Adolescent; Adult; Dermatologic Agents; Face; Female; Humans; Male; Nicotinic Acids; | 2010 |
Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris.
Topics: Acne Vulgaris; Administration, Topical; Adolescent; Adult; Anti-Inflammatory Agents; Child; Dapsone; | 2011 |
Pharmacokinetics of tazarotene cream 0.1% after a single dose and after repeat topical applications at clinical or exaggerated application rates in patients with acne vulgaris or photodamaged skin.
Topics: Acne Vulgaris; Administration, Topical; Adolescent; Adult; Female; Humans; Male; Nicotinic Acids; Oi | 2003 |
Topical tazarotene: The BEST (balancing efficacy, speed, and tolerability) in acne trial.
Topics: Acne Vulgaris; Administration, Cutaneous; Adult; Anti-Bacterial Agents; Benzoyl Peroxide; Clindamyci | 2004 |
Cumulative irritation potential of adapalene 0.1% cream and gel compared with tazarotene cream 0.05% and 0.1%.
Topics: Acne Vulgaris; Adapalene; Adult; Aged; Dermatologic Agents; Dose-Response Relationship, Drug; Drug A | 2005 |
Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study.
Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Child; Dermato | 2006 |
Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double-blind, randomized parallel-group trial.
Topics: Acne Vulgaris; Administration, Cutaneous; Adult; Anti-Bacterial Agents; Benzoyl Peroxide; Clindamyci | 2006 |
Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study.
Topics: Acne Vulgaris; Administration, Oral; Adult; Anti-Bacterial Agents; Dermatologic Agents; Double-Blind | 2006 |
Tazarotene 0.1 percent cream plus clindamycin 1 percent gel versus tretinoin 0.025 percent gel plus clindamycin 1 percent gel in the treatment of facial acne vulgaris.
Topics: Acne Vulgaris; Administration, Topical; Adolescent; Adult; Anti-Bacterial Agents; Child; Clindamycin | 2007 |
Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study.
Topics: Acne Vulgaris; Adolescent; Adult; Double-Blind Method; Female; Gels; Humans; Keratolytic Agents; Mal | 1999 |
Comparison of treatment of acne vulgaris with alternate-day applications of tazarotene 0.1% gel and once-daily applications of adapalene 0.1% gel: a randomized trial.
Topics: Acne Vulgaris; Adapalene; Adolescent; Adult; Child; Dermatologic Agents; Double-Blind Method; Female | 2001 |
Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial.
Topics: Acne Vulgaris; Adolescent; Adult; Child; Double-Blind Method; Female; Gels; Humans; Keratolytic Agen | 2001 |
Randomized facial tolerability studies comparing gel formulations of retinoids used to treat acne vulgaris.
Topics: Acne Vulgaris; Adolescent; Adult; Child; Double-Blind Method; Gels; Humans; Keratolytic Agents; Nico | 2001 |
Successful treatment of acne vulgaris using a new method: results of a randomized vehicle-controlled trial of short-contact therapy with 0.1% tazarotene gel.
Topics: Acne Vulgaris; Adolescent; Adult; Child; Female; Gels; Humans; Male; Nicotinic Acids; Remission Indu | 2002 |
Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy.
Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Anti-Bacterial Agents; Benzoyl Peroxide | 2002 |
Once-daily tazarotene 0.1 % gel versus once-daily tretinoin 0.1 % microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial.
Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Child; Cost-Benefit Analysis; Dermatolo | 2002 |
A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris.
Topics: Acne Vulgaris; Adapalene; Administration, Cutaneous; Adolescent; Adult; Child; Cost-Benefit Analysis | 2002 |
17 other studies available for tazarotene and Acne
| Article | Year |
|---|---|
Development of a Tape-Stripping Liquid Chromatography-Mass Spectrometry Method for Evaluating Skin Deposition of Topical Tazarotene.
Topics: Acne Vulgaris; Adult; Chromatography, Liquid; Female; Humans; Mass Spectrometry; Nicotinic Acids; Se | 2021 |
In Vitro Rheology Predicts Improved Spreadability of Tazarotene 0.045% Lotion Versus Trifarotene 0.005% Cream.
Topics: Acne Vulgaris; Administration, Cutaneous; Adult; Dermatologic Agents; Double-Blind Method; Humans; N | 2022 |
Efficacy and Safety of Tazarotene Lotion, 0.045% in the Treatment of Truncal Acne Vulgaris.
Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Child; Dermatologic Agents; Double-Blin | 2022 |
Tazarotene Lotion 0.045% for the Treatment of Acne
Topics: Acne Vulgaris; Administration, Cutaneous; Dermatologic Agents; Emollients; Emulsions; Humans; Nicoti | 2022 |
ARAZLO (Tazarotene 0.045%) Lotion for Topical Treatment of Acne Vulgaris.
Topics: Acne Vulgaris; Administration, Topical; Adolescent; Adult; Dermatologic Agents; Female; Gels; Humans | 2020 |
Novel Polymeric Lotion Formulation of Once-Daily Tazarotene (0.045%) for Moderate-to-Severe Acne: Pooled Phase 3 Analysis.
Topics: Acne Vulgaris; Adolescent; Adult; Aged; Child; Clinical Trials, Phase III as Topic; Double-Blind Met | 2020 |
The only topical retinoid without a generic alternative: tazarotene.
Topics: Acne Vulgaris; Dermatologic Agents; Drug Approval; Drugs, Generic; Humans; Nicotinic Acids; Psoriasi | 2013 |
A status report on topical tazarotene in the management of acne vulgaris.
Topics: Acne Vulgaris; Administration, Cutaneous; Animals; Dermatologic Agents; Drug Approval; Drug Therapy, | 2013 |
Novel microemulsion-based gel formulation of tazarotene for therapy of acne.
Topics: Acne Vulgaris; Animals; Chemistry, Pharmaceutical; Drug Delivery Systems; Drug Stability; Emulsions; | 2016 |
Tazarotene foam, 0.1%, for the treatment of acne.
Topics: Acne Vulgaris; Administration, Cutaneous; Dermatologic Agents; Humans; Medication Adherence; Nicotin | 2016 |
Topical retinoids for acne.
Topics: Acne Vulgaris; Adapalene; Administration, Cutaneous; Dermatologic Agents; Humans; Nicotinic Acids; R | 2016 |
Journal of Drugs in Dermatology: New methods and Techniques. Managing acne with adapalene 0.1% and 0.3% gels. Introduction.
Topics: Acne Vulgaris; Adapalene; Adolescent; Child; Dermatologic Agents; Drug Therapy, Combination; Humans; | 2008 |
Topical tazarotene in acne vulgaris: treatment approaches.
Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Asian; Black or African American; Clima | 2004 |
Effects of tazarotene 0.1 % cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials.
Topics: Acne Vulgaris; Administration, Topical; Adolescent; Adult; Child; Dermatologic Agents; Double-Blind | 2004 |
Combining clindamycin 1%-benzoyl peroxide 5% gel with multiple therapeutic options.
Topics: Acne Vulgaris; Adapalene; Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Anti-B | 2006 |
Topical retinoid introduced for plaque psoriasis, acne vulgaris.
Topics: Acne Vulgaris; Dermatologic Agents; Humans; Nicotinic Acids; Prodrugs; Psoriasis; Retinoids | 1997 |
Tazarotene (tazorac) for acne.
Topics: Acne Vulgaris; Dermatologic Agents; Humans; Keratolytic Agents; Nicotinic Acids | 2002 |